Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats

被引：0

作者：

Sáez-Torres, I

Espejo, C

Pérez, JJ

Acarín, N

Montalban, X

Martínez-Cáceres, EM

机构：

[1] Univ Autonoma Barcelona, Hosp Gen Valle Hebron, Dept Neurol, Unitat Neuroimmunol Clin, Barcelona 08035, Spain

[2] Univ Politecn Catalunya, ETSEIB, Dept Engn Quim, Barcelona, Spain

来源：

CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2000年 / 121卷 / 01期

关键词：

experimental autoimmune encephalomyelitis; peptide T; Lewis rat; multiple sclerosis;

D O I：

10.1046/j.1365-2249.2000.01259.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different doses and phases of the disease according to several treatment protocols, but we could not observe a consistent effect of peptide T ameliorating the disease. Lymph node cell proliferation and IL-4 and interferon-gamma production were also studied. We conclude that peptide T neither prevents nor ameliorates EAE in Lewis rats.

引用

页码：151 / 156

页数：6

共 36 条

[1]

BUENAFE AC, 1995, J IMMUNOL, V155, P1556

[2] GENETIC-VARIATION IN THE ABILITY OF SEVERAL STRAINS OF RATS TO PRODUCE INTERFERON IN RESPONSE TO POLYRIBOINOSINIC-POLYRIBOCYTODILIC ACID [J].

DAVIS, CT ;

BLANKENHORN, EP ;

MURASKO, DM .

INFECTION AND IMMUNITY, 1984, 43 (02) :580-583

[3] PEPTIDE-T IMPROVES PSORIASIS WHEN INFUSED INTO LESIONS IN NANOGRAM AMOUNTS [J].

FARBER, EM ;

COHEN, EN ;

TROZAK, DJ ;

WILKINSON, DI .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (04) :658-664

[4] Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms [J].

Gaur, A ;

Boehme, SA ;

Chalmers, D ;

Crowe, PD ;

Pahuja, A ;

Ling, N ;

Brocke, S ;

Steinman, L ;

Conlon, PJ .

JOURNAL OF NEUROIMMUNOLOGY, 1997, 74 (1-2) :149-158

[5]

Goverman J, 1996, LAB ANIM SCI, V46, P482

[6] INFLAMMATORY MEDIATORS IN DEMYELINATING DISORDERS OF THE CNS AND PNS [J].

HARTUNG, HP ;

JUNG, SF ;

STOLL, G ;

ZIELASEK, J ;

SCHMIDT, B ;

ARCHELOS, JJ ;

TOYKA, KV .

JOURNAL OF NEUROIMMUNOLOGY, 1992, 40 (2-3) :197-210

[7]

Heber-Katz E, 1993, Int Rev Immunol, V9, P277, DOI 10.3109/08830189309051211

[8] Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment [J].

Heseltine, PNR ;

Goodkin, K ;

Atkinson, JH ;

Vitiello, B ;

Rochon, J ;

Heaton, RK ;

Eaton, EM ;

Wilkie, FL ;

Sobel, E ;

Brown, SJ ;

Feaster, D ;

Schneider, L ;

Goldschmidts, WL ;

Stover, ES .

ARCHIVES OF NEUROLOGY, 1998, 55 (01) :41-51

[9]

KLEINERMAN ES, 1987, J IMMUNOL, V139, P2329

[10] Treatment of early AIDS dementia in intravenous drug users: High versus low dose peptide T [J].

Kosten, TR ;

Rosen, MI ;

McMahon, TL ;

Bridge, TP ;

OMalley, SS ;

Pearsall, R ;

OConnor, PG .

AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 1997, 23 (04) :543-553

← 1 2 3 4 →